ResMed is in a recovery uptrend within a broader one-year consolidation. The stock is up 29.49% over three months and 15.01% over six months, yet still down 4.67% over the trailing year — a profile consistent with a bottoming-and-rebuilding pattern rather than a sustained advance. At $252.86, the shares sit at roughly 74% of the 52-week range (low $180.27, high $277.67), meaning they have reclaimed most of the ground lost during the drawdown but have not yet challenged the highs; the maximum drawdown of -35.46% over the period underscores how violent the prior decline was, and the current position suggests momentum is rebuilding rather than overextended.

Short-term momentum is decisively positive and accelerating. The stock has gained 13.75% in the past month versus a -1.02% decline for the S&P 500, producing a relative strength of +14.77 percentage points — a sharp positive divergence from the -17.80 percentage point relative underperformance over the full year. The three-month relative strength of +26.64 points confirms this is a genuine trend reversal rather than a one-month blip, and the 1-month gain of 13.75% against the 3-month gain of 29.49% implies the pace of advance is roughly steady rather than decelerating. Volume of approximately 1.01 million shares is moderate, and the short ratio of 10.02 days (heavy short interest relative to average volume) raises the possibility that part of the recent rally reflects short covering, which can amplify moves but also makes them more fragile.

Key technical levels are well defined. Resistance sits at the 52-week high of $277.67 — roughly 9.8% above the current $252.86 — and a decisive breakout above that level would signal the market has fully digested the GLP-1 and competitive overhangs and could open a new leg higher. Support rests at the 52-week low of $180.27, about 28.7% below current levels, with intermediate support likely in the $220–$230 zone where the stock consolidated through September. With a beta of just 0.75, ResMed is roughly 25% less volatile than the market, which argues for larger position sizing tolerance but also means the recent 13.75% monthly move is unusually large for this name — a sign of genuine re-rating rather than beta-driven drift.

Revenue growth is steady and modestly accelerating. Fiscal Q4 2026 (quarter ended June 30, 2026) revenue was $1.464 billion, up 8.58% year over year, and the sequential progression tells a consistent story: $1.336 billion in Q1, $1.423 billion in Q2, $1.431 billion in Q3, and $1.464 billion in Q4 — four consecutive quarterly records with growth in the high-single digits. Segment data shows Sleep and Respiratory contributing $1.256 billion versus $166.9 million from Residential Care Software, confirming that the core sleep franchise (devices plus the recurring mask and consumable annuity) remains the growth engine, while the smaller software business is a margin and stickiness enhancer rather than a growth driver. Consensus revenue estimates of approximately $7.06 billion for the forward period imply continued high-single-digit expansion, consistent with the structural tailwinds of rising sleep apnea diagnosis and an aging, increasingly obese population.

Profitability is robust and margins are expanding. Q4 2026 net income was $383.4 million on a 26.2% net margin, with gross margin of 58.84% and operating margin of 30.66%; notably, gross margin has climbed from 58.60% in the year-ago quarter and from 61.46% in Q1 2026, while the trailing-twelve-month gross margin of 61.06% and operating margin of 33.76% reflect the benefit of manufacturing efficiencies and a favorable mix toward high-margin masks. Net income has grown from $348.5 million in Q1 2026 to $383.4 million in Q4 2026, and diluted EPS rose from $2.37 to $2.64 over the same span. A 26.9% net margin and 33.8% operating margin are well above the medical devices industry norm, reflecting pricing power in a duopoly and the recurring nature of consumable revenue.

Balance sheet and cash generation are fortress-like. Debt-to-equity is just 0.125, the current ratio is a very comfortable 3.10, and return on equity is 23.1% with return on assets of 14.0%. Trailing free cash flow is $2.89 billion against a market cap of roughly $28.2 billion — an FCF yield of about 10.2% — and the company returned capital aggressively in fiscal 2026, repurchasing $700.0 million of stock and paying $349.7 million in dividends while still growing cash to $1.469 billion. Operating cash flow of $1.806 billion comfortably funded $156.3 million of capex and $350.7 million of acquisitions, demonstrating that ResMed funds growth internally with room to spare; the 1.24% dividend yield with a payout ratio of just 22.95% leaves ample capacity for further increases.